Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

Classic psychedelics are being studied as treatments for a range of disorders, and their therapeutic effects appear to depend partly on the quality of the acute subjective experience. The paper notes that mystical-type experience, often measured with the Mystical Experience Questionnaire (MEQ), has been linked in earlier research to improvements in depression, anxiety, life satisfaction, and substance use. At the same time, psychedelic sessions are usually supported by two facilitators, yet it has been unclear whether individual facilitators meaningfully shape participants’ experiences. The authors frame this as an important gap because, if facilitators influence subjective effects, this would affect how psychedelic therapy should be understood and standardised. P. and colleagues set out to examine whether session facilitators account for variation in acute subjective effects during psilocybin administration sessions, and whether this differs between clinical populations and healthy volunteers. They present what they describe as the largest and most comprehensive analysis to date of facilitator influence on psilocybin experiences, using pooled trial data from the Johns Hopkins Centre for Psychedelic and Consciousness Research. The aim was to quantify how much of the variation in MEQ scores could be attributed to facilitators after accounting for participant, dose, and study-level differences.

The researchers pooled participant-level data from 9 psilocybin administration studies conducted at the Johns Hopkins Centre for Psychedelic and Consciousness Research. The dataset included completed clinical trials in anorexia, major depressive disorder, and cancer-related existential distress, as well as pharmacological studies in healthy volunteers. Altogether, the studies involved at least one high oral dose of psilocybin per trial; only dosing sessions in which psilocybin or placebo was administered were included in the analysis. Two session facilitators were assigned to each participant. Across trials, participants met with both facilitators before, during, and after dosing sessions to build rapport, receive psychoeducation, be monitored for safety, and discuss experiences afterwards. The number of dosing sessions per participant varied from 1 to 5. Subjective effects were assessed around 6 hours after administration, once the immediate acute effects had subsided. The main outcome was the MEQ, either the 30-item version or the 100-item States of Consciousness Questionnaire, which includes the MEQ items. The researchers also included dose, dosing session number, facilitator experience measured as number of sessions monitored, participant ID, and study number. MEQ total and subscale scores were converted to a proportion of the maximum possible score. To analyse the nested structure of the data, the authors used multilevel models in R, specifically a multiple membership model that allowed each session to be associated with two facilitators. The main model regressed total MEQ score on fixed effects of dose, session number, facilitator experience, and study number, with random intercepts for participant and facilitator. They estimated the variance partition coefficient to quantify how much variance in MEQ scores was attributable to facilitators and participants. They also split the dataset into clinical and healthy-volunteer subsets and used a bootstrap procedure with 5,000 resamples to test whether facilitator-level variance differed between the two groups.

The final sample comprised 298 participants, 670 dosing sessions, and 60 unique session facilitators. Of these, 97 participants and 211 sessions were in clinical samples, and 201 participants and 459 sessions were in healthy-volunteer studies. Across the full dataset, facilitator-level variance in MEQ scores was extremely small, with a random-effect variance of 0.001 and a variance partition coefficient of 1.6%. The individual facilitator effects were described as nil to negligible, and every facilitator’s 95% confidence interval included 0, suggesting no clear deviation from the average MEQ score. By contrast, participant-level variance was much larger, with a variance of 0.026 and a variance partition coefficient of 43.2%. When the samples were analysed separately, facilitator effects were much larger in clinical studies than in healthy-volunteer studies. In clinical samples, facilitator variance was 0.009, corresponding to 13.6% of MEQ variance, whereas in healthy volunteers it was 0.0005, corresponding to 0.8%. Participant-level variance remained substantial in both groups, at 30.4% in clinical samples and 41.9% in healthy volunteers. The bootstrap comparison indicated that facilitator variance was significantly greater in clinical than healthy studies, with a 95% confidence interval of -0.003 to 0.058 and p = .012. The paper indicates that additional analyses of MEQ subfactors were available in the Supporting Information, but those results are not detailed in the extracted text.

The authors interpret their findings as showing that facilitators matter very little for acute subjective effects in healthy volunteers, but meaningfully in clinical populations. They argue that the 13.6% facilitator-associated variance seen in clinical samples is clinically relevant and comparable to, or larger than, therapist effects reported in traditional psychotherapy research. In their view, this suggests that interpersonal and contextual features of the facilitator may be especially important when participants are dealing with mental health conditions, psychological vulnerability, or stronger therapeutic expectations. The discussion links these findings to earlier psychedelic research indicating that therapeutic alliance is associated with stronger mystical-type experience, emotional breakthrough, psychological insight, and downstream symptom improvement. The authors suggest that the facilitator-participant relationship may be particularly consequential in clinical psychedelic therapy, whereas healthy volunteers may rely more on pharmacological effects and individual traits. They also propose that, in healthy-volunteer studies, the facilitator role may be sufficiently limited that trained non-licensed facilitators could be adequate, while patient populations may require clinically trained facilitators because psychotherapeutic elements may be more consequential. The authors acknowledge several limitations. The analysis relied primarily on MEQ scores, so it does not address other measures that might be more sensitive to facilitator influence, such as connectedness, insight, emotional breakthrough, or specific emotions like awe. The data came from a single academic centre with highly standardised procedures, extensive training, medical oversight, and recorded sessions, which may reduce between-facilitator variability and limit generalisability to other settings. The study also included only oral psilocybin, so the authors caution that other psychedelics or faster-onset routes of administration might show different patterns. They note that different indications, levels of illness severity, and levels of psychological support could also alter the extent of facilitator influence. The authors’ broader implication is that standardising and improving facilitator training could help make psychedelic treatment effects more consistent, especially in clinical populations. They also emphasise that future work should examine facilitator effects across other psychedelics, other measures of experience, and more diverse real-world settings.

The authors conclude that facilitator effects are a meaningful source of variability in psilocybin experiences in clinical samples, but not in healthy volunteers, and that these effects are comparable to or greater than therapist effects in conventional psychotherapy. They state that this work provides a basis for future studies to separate the roles of facilitator, context, and individual differences in shaping therapeutic outcomes, and it supports efforts to improve facilitator training as psychedelic-assisted therapies move towards wider clinical implementation.